Viva Biotech Holdings Past Earnings Performance

Past criteria checks 0/6

Viva Biotech Holdings's earnings have been declining at an average annual rate of -23.5%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 32.6% per year.

Key information

-23.5%

Earnings growth rate

-22.7%

EPS growth rate

Life Sciences Industry Growth41.4%
Revenue growth rate32.6%
Return on equity0.8%
Net Margin-0.02%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Aug 30
Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19
Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03
Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26
A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19
Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01
Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11
Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14
These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Dec 23
Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Nov 06
Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Jun 13
Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Apr 17
We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13
Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06
Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02
What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21
Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Revenue & Expenses Breakdown

How Viva Biotech Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:1873 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241,995038994
31 Mar 242,075-58403111
31 Dec 232,156-116418128
30 Sep 232,284-276417150
30 Jun 232,413-436416172
31 Mar 232,396-482413154
31 Dec 222,380-528410136
30 Sep 222,283-209398116
30 Jun 222,18611138596
31 Mar 222,14519935394
31 Dec 212,10428832292
30 Sep 211,81525827187
30 Jun 211,52622821981
31 Mar 211,111-7917174
31 Dec 20697-38712366
30 Sep 20538-3499659
30 Jun 20378-3117052
31 Mar 20351-236248
31 Dec 193232665545
30 Sep 192991764837
30 Jun 19275864230
31 Mar 19243883627
31 Dec 18210913025
31 Dec 17148761717
31 Dec 1696241417

Quality Earnings: 1873 is currently unprofitable.

Growing Profit Margin: 1873 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1873 is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.

Accelerating Growth: Unable to compare 1873's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1873 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.4%).


Return on Equity

High ROE: 1873 has a negative Return on Equity (0.81%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies